DUBLIN and MYSTIC, Conn., Aug. 3 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) has scheduled a conference call for Tuesday, August 10, 2010 at 4:00 pm UTC/GMT + 1 hour (11:00 am Eastern Time) to discuss selected financial results and provided a progress update of the Company’s MARINE and ANCHOR, the two Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.
The conference call may be heard live via the investor relations section of the Company’s website at www.amarincorp.com and will also be available by dialing the following numbers:
From outside U.S. dial-in: | (201) 689-8565 | |
From inside U.S. dial-in: | (877) 407-0778 | |
Replay is available will be made available for a period of two weeks following the conference calls. To hear a replay of the call, dial 1-201-612-7415 (outside U.S.) and 1-877-660-6853 (inside U.S.) For both dial in numbers please use account number is 286 and conference id 354659.
About Amarin
Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company’s lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials were designed under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.
Contacts: | |
Investor Contact Information: | |
John F. Thero | |
Chief Financial Officer | |
In U.S.: +1 (860) 572 4979 | |
Lee M. Stern | |
The Trout Group | |
In U.S.: +1 (646) 378-2922 | |
International Media Contact Information: | |
Mark Swallow or David Dible | |
Citigate Dewe Rogerson | |
In UK: +44 (0)207 638 9571 | |
SOURCE Amarin Corporation plc
